Drug
Valoctocogene Roxaparvovec
Valoctocogene Roxaparvovec: highest development phase Phase 3, developed by BioMarin Pharmaceutical. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- BioMarin Pharmaceutical
Trials
| Drug | Phase | Indication |
|---|---|---|
| Valoctocogene roxaparvovec NCT06224907 | Phase 3 | Hemophilia A |
| Valoctocogene roxaparvovec NCT04684940 | Phase 1/2 | Hemophilia A With Inhibitor |
Latest
No recent events.
Follow Valoctocogene Roxaparvovec on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.